Skip to content
Ep. 112 -  Digesting DDR Data; Plus Sharpless’ Legacy, McKinsey’s Conflicts episode artwork

Apr 19, 2022 20 min

Ep. 112 - Digesting DDR Data; Plus Sharpless’ Legacy, McKinsey’s Conflicts

from BioCentury This Week Hosted by BioCentury

Long-awaited proof of concept for AstraZeneca’s PARP-1-selective therapy opens the door to combination strategies previously limited by hematopoietic toxicity, Senior Editor Karen Tkach Tuzman says on the latest edition of BioCentury This Week. Tkach Tuzman surveys data from the growing DNA damage repair (DDR) field from this year’s American Association for Cancer Research meeting, and the team also discusses the legacy of outgoing NCI Director Ned Sharpless, concerns over McKinsey's work for FDA and life sciences clients and the latest crop of BioCentury Emerging Company Profiles. This week’s podcast is sponsored by Bio€quity Europe. Reach us by sending a text

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Ep. 112 - Digesting DDR Data; Plus Sharpless’ Legacy, McKinsey’s Conflicts

0:00 20:23

Chapters

  1. 1:49 DDR Data at AACR
  2. 5:54 Ned Sharpless' Legacy at NCI
  3. 7:49 McKinsey: Concerns over Conflict
  4. 12:52 Emerging Company Spotlight

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of BioCentury This Week?

This episode is 20 minutes long.

When was this BioCentury This Week episode published?

This episode was published on April 19, 2022.

Can I download this BioCentury This Week episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.